Opinion

Video

Closing the Gaps: Therapeutic Performance and the Promise of Innovation

Panelists discuss how current multiple sclerosis (MS) therapies show limited effectiveness against progression, but emerging Bruton tyrosine kinase (BTK) inhibitors offer promise by targeting both B cells and central nervous system (CNS)–penetrating microglia, with one showing a 31% reduction in confirmed disability progression in clinical trials.

Video content above is prompted by the following:

Current therapeutic options for addressing disability progression in MS, particularly in progressive forms, remain severely limited and often inadequate. For primary progressive MS, only 1 FDA-approved treatment exists: ocrelizumab, a humanized anti-CD20 monoclonal antibody. Despite positive phase 3 trial results against placebo, ocrelizumab’s performance is modest—it slows but doesn’t stop progression, and its efficacy diminishes significantly after patients are aged 53 to 55 years. Notably, this systemic immune system–targeting antibody achieves only 0.1% CNS penetration, highlighting the challenge of addressing CNS-confined pathological processes.

The therapeutic landscape for secondary progressive MS faces similar challenges. While 1 second-generation S1P receptor modulator showed positive results in secondary progressive MS trials, FDA approval was limited to relapsing forms because the progression-slowing benefits primarily occurred in patients closer to the relapsing phase, rather than those with established progressive disease. This regulatory decision underscores the difficulty in developing treatments specifically for established progressive MS and the need for more targeted therapeutic approaches.

Emerging BTK inhibitors represent a promising new therapeutic class that may address these unmet needs. These oral agents target both B cells and myeloid cells (monocytes, macrophages) while offering crucial CNS penetration to impact microglia—a key component of the smoldering inflammation underlying progressive MS. The positive HERCULES trial results showed a 31% reduction in confirmed disability progression over 6 months compared with placebo in patients with nonrelapsing secondary progressive MS. Current phase 3 trials are testing distinct BTK inhibitors in primary progressive MS, with one comparing against placebo and another against ocrelizumab as the gold standard, potentially offering new hope for patients with limited treatment options.

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Videos
2 experts in this video
5 experts are featured in this series
1 expert is featured in this series.
4 experts are featured in this series.
4 experts are featured in this series.
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo